Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.

Employees

510

Sector

Biotechnology & Medical Research

Calendar

03-02 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
12/12/25	27.36 $	-0.55%	1,562,898
11/12/25	27.51 $	+0.40%	1,396,240
10/12/25	27.40 $	+3.47%	1,640,936
09/12/25	26.48 $	-2.29%	1,117,415
08/12/25	27.10 $	+0.04%	1,531,927

Delayed Quote Nasdaq, December 12, 2025 at 09:00 pm

More quotes

Income Statement and Estimates

More financial data

Analysis / Opinion

Beam CEO Andy Bromberg: Bitcoin ETFs a financialisation away from the original essence of crypto

January 30, 2024 at 07:17 pm

More Strategies

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

27.36USD

Average target price

45.93USD

Spread / Average Target

+67.87%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 21:00:00 12/12/2025 GMT			5-day change	1st Jan Change
27.36 ^USD	-0.55%		+1.00%	+10.32%

12-06	Beam Therapeutics Inc. Reports Updated Data from BEACON Phase 1/2 Trial of Ristoglogene Autogetemcel (risto-cel)	CI
11-04	Beam Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

Capitalization	2.7B 2.3B 2.15B 2.02B 3.72B 245B 4.07B 25.08B 9.73B 115B 10.13B 9.92B 421B	P/E ratio 2025 *	-6.14x	P/E ratio 2026 *	-5.98x
Enterprise value	2.7B 2.3B 2.15B 2.02B 3.72B 245B 4.07B 25.08B 9.73B 115B 10.13B 9.92B 421B	EV / Sales 2025 *	68.8x	EV / Sales 2026 *	61.1x
Free-Float	98.59%	Yield 2025 *	-	Yield 2026 *	-

12-06	Beam Therapeutics Inc. Reports Updated Data from BEACON Phase 1/2 Trial of Ristoglogene Autogetemcel (risto-cel)	CI
11-04	Beam Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-04	Earnings Flash (BEAM) Beam Therapeutics Inc. Reports Q3 Revenue $9.7M, vs. FactSet Est of $11.3M	MT
11-04	Beam Therapeutics Q3 net loss wider than expected on higher R&D expenses	RE
10-09	Jefferies Initiates Beam Therapeutics at Buy Rating, $41 Price Target	MT
10-13	Beam Therapeutics Inc. Presents at Wells Fargo 20th Annual Healthcare Conference 2025, Sep-04-2025 01:30 PM
09-09	Beam Therapeutics Inc. Presents at H.C. Wainwright 27th Annual Global Investment Conference, Sep-08-2025 10:30 AM
10-03	Beam Therapeutics Inc. Presents at Citi's Biopharma Back to School Conference, Sep-03-2025 04:00 PM
08-14	Sector Update: Health Care Stocks Decline Premarket Thursday	MT
08-14	Beam Therapeutics Gets FDA Regenerative Medicine Status for BEAM-101 to Treat Sickle Cell Disease	MT
08-14	Beam Therapeutics Inc. Announces U.S. FDA Regenerative Medicine Advanced Therapy Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease	CI
08-14	Beam Therapeutics' Sickle Cell Treatment Gets FDA's Generative Medicine Advanced Therapy Designation	DJ
08-05	Beam Therapeutics Q2 Net Loss Narrows, Revenue Falls	MT

10-09	Jefferies Initiates Beam Therapeutics at Buy Rating, $41 Price Target	MT
04-03	RBC Cuts Price Target on Beam Therapeutics to $20 From $26, Keeps Sector Perform, Speculative Risk	MT
03-28	BofA Securities Upgrades Beam Therapeutics to Buy From Neutral	MT
03-10	Scotiabank Upgrades Beam Therapeutics to Sector Outperform From Sector Perform, $40 Price Target	MT
02-26	RBC Raises Price Target on Beam Therapeutics to $26 From $24, Keeps Sector Perform, Speculative Risk	MT

Beam Therapeutics Inc. Share Price

Equities

BEAM

US07373V1052

Biotechnology & Medical Research

Valuation: Beam Therapeutics Inc.

Chart: Beam Therapeutics Inc.

Latest news: Beam Therapeutics Inc.

Last Transcript: Beam Therapeutics Inc.

Analysts' recommendations: Beam Therapeutics Inc.

Press Releases: Beam Therapeutics Inc.

News in other languages: Beam Therapeutics Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Beam Therapeutics Inc.

ETFs: Beam Therapeutics Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysis / Opinion

Analysts' Consensus

Quarterly revenue - Rate of surprise

12-09	Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions	AQ
12-06	Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting	GL
11-12	Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference	GL
11-04	Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates	GL
11-04	Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates	AQ

11/01/22	Pfizer dice que probablemente se necesite una nueva vacuna contra ómicron
11/01/22	Airbus : contrat avec Azorra pour 22 appareils A220
10/01/22	MÄRKTE USA/Kräftige Erholung trotz anhaltender Zinssorgen
10/01/22	MÄRKTE USA/Wall Street mit anhaltenden Zinssorgen unter Druck
10/01/22	Pfizer: trois accords pour renforcer ses capacités sur l'ARN messager

1 day	-0.55%
1 week	+1.00%
Current month	+8.01%
1 month	+26.32%
3 months	+32.82%
6 months	+60.38%
Current year	+10.32%

1 week	25.86	28.28
1 month	20.23	29.16
Current year	13.52	35.25
1 year	13.52	35.25
3 years	13.52	50.74
5 years	13.52	138.52
10 years	13	138.52

Manager	Title	Age	Since
John Evans CEO	Chief Executive Officer	47	31/12/2016
Sravan Emany DFI	Director of Finance/CFO	47	18/12/2024
Giuseppe Ciaramella PSD	President	56	23/01/2020

Director	Title	Age	Since
John Evans BRD	Director/Board Member	47	31/12/2016
Mark Fishman BRD	Director/Board Member	74	30/04/2018
Carole Ho BRD	Director/Board Member	52	14/11/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
BEAM THERAPEUTICS INC.	-0.55%	+1.00%	-2.04%	-40.18%	2.7B
LONZA GROUP AG	-1.79%	-5.23%	-3.38%	+8.38%	45.43B
IQVIA HOLDINGS INC.	-1.65%	-1.59%	+11.65%	+2.52%	37.85B
BEONE MEDICINES AG	-0.55%	-1.19%	+77.90%	+53.34%	35.31B
CELLTRION, INC.	+0.05%	+1.91%	+5.47%	+18.52%	27.66B
MEDPACE HOLDINGS, INC.	-1.46%	+1.78%	+61.28%	+159.86%	15.72B
REVOLUTION MEDICINES, INC.	+0.52%	-0.90%	+75.34%	+238.71%	15.26B
ICON PUBLIC LIMITED COMPANY	-1.76%	+0.38%	-10.36%	-5.89%	14.25B
ASCENDIS PHARMA A/S	+4.88%	+7.29%	+69.72%	+79.48%	13.47B
IONIS PHARMACEUTICALS, INC.	+2.12%	-1.05%	+120.76%	+111.96%	13.09B
Average	-0.02%	+0.03%	+40.63%	+62.67%	22.07B
Weighted average by Cap.	-0.50%	-1.08%	+34.74%	+51.51%

	2025 *	2026 *
Net sales	39.27M 33.45M 31.25M 29.4M 54.13M 3.56B 59.14M 365M 141M 1.68B 147M 144M 6.12B	44.22M 37.67M 35.19M 33.1M 60.95M 4B 66.58M 411M 159M 1.89B 166M 162M 6.89B
Net income	-441M -376M -351M -330M -608M -39.93B -664M -4.09B -1.59B -18.82B -1.65B -1.62B -68.67B	-486M -414M -387M -364M -671M -44.06B -733M -4.52B -1.75B -20.77B -1.83B -1.79B -75.77B
Net Debt	-	-